Dashenlin Pharm Grp Co Ltd
DaShenLin Pharmaceutical Group Co., Ltd. manufactures, distributes, and retails pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and antler tonic medicinal materials, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.
Dashenlin Pharm Grp Co Ltd (603233) - Total Liabilities
Latest total liabilities as of September 2025: CN¥17.59 Billion CNY
Based on the latest financial reports, Dashenlin Pharm Grp Co Ltd (603233) has total liabilities worth CN¥17.59 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Dashenlin Pharm Grp Co Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Dashenlin Pharm Grp Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Dashenlin Pharm Grp Co Ltd Competitors by Total Liabilities
The table below lists competitors of Dashenlin Pharm Grp Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lufax Holding Ltd
NYSE:LU
|
USA | $120.11 Billion |
|
AQ Group AB (publ)
F:7AQ0
|
Germany | €2.42 Billion |
|
Xinxiang Richful Lube Additive Co. Ltd
SHE:300910
|
China | CN¥1.10 Billion |
|
Takeuchi Mfg. Co., Ltd.
OTCGREY:TKUGF
|
USA | $41.34 Billion |
|
3M India Limited
NSE:3MINDIA
|
India | ₹10.48 Billion |
|
Ningbo Xusheng Auto Technology Co Ltd
SHG:603305
|
China | CN¥6.32 Billion |
|
Yinson Holdings Bhd
KLSE:7293
|
Malaysia | RM21.16 Billion |
|
Ducgiang Chemicals & Detergent Powder Joint Co
VN:DGC
|
Vietnam | ₫4.14 Trillion |
Liability Composition Analysis (2012–2024)
This chart breaks down Dashenlin Pharm Grp Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dashenlin Pharm Grp Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dashenlin Pharm Grp Co Ltd (2012–2024)
The table below shows the annual total liabilities of Dashenlin Pharm Grp Co Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥18.30 Billion | +13.04% |
| 2023-12-31 | CN¥16.19 Billion | +15.83% |
| 2022-12-31 | CN¥13.98 Billion | +22.61% |
| 2021-12-31 | CN¥11.40 Billion | +68.66% |
| 2020-12-31 | CN¥6.76 Billion | +55.73% |
| 2019-12-31 | CN¥4.34 Billion | +25.79% |
| 2018-12-31 | CN¥3.45 Billion | +14.25% |
| 2017-12-31 | CN¥3.02 Billion | +34.94% |
| 2016-12-31 | CN¥2.24 Billion | +36.70% |
| 2015-12-31 | CN¥1.64 Billion | -8.55% |
| 2014-12-31 | CN¥1.79 Billion | +64.11% |
| 2013-12-31 | CN¥1.09 Billion | +77.27% |
| 2012-12-31 | CN¥615.39 Million | -- |